A COX-2 inhibitor
Related Products
Labeled Version(s)
26598Bromfenac-d4 (sodium salt)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Bromfenac (sodium salt)

Item No. 23763

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-amino-3-(4-bromobenzoyl)-benzeneacetic acid, monosodium salt
CAS Number
91714-93-1
Synonyms
  • AHR 10282B
Molecular Formula
C15H11BrNO3 • Na
Formula Weight
356.2
Purity
≥99%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: 100 mMEthanol: 5 mMWater: 100 mM
SMILES
BrC1=CC=C(C(C2=CC=CC(CC([O-])=O)=C2N)=O)C=C1.[Na+]
InChi Code
InChI=1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1
InChi Key
HZFGMQJYAFHESD-UHFFFAOYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $81

    Add

    50 mg

    $317

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Bromfenac is an inhibitor of cyclooxygenase 2 (COX-2; IC50 = 6.6 nM) that is selective over COX-1 (IC50 = 210 nM).1 It inhibits prostaglandin E2 (PGE2; Item No. 14010) production in a rabbit model of LPS-induced eye inflammation. Bromfenac also decreases inflammation following cataract removal in dogs when administered as a 0.9% topical solution on a tapering schedule for 24 weeks.2 Formulations containing bromfenac have been used in the treatment of postoperative inflammation following cataract surgery.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Waterbury, L.D., Silliman, D., and Jolas, T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr. Med. Res. Opin. 22(6), 1133-1140 (2006).

    2. Brookshire, H.L., English, R.V., Nadelstein, B., et al. Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal. Vet. Ophthalmol. 18(3), 175-185 (2015).